JP2015534970A5 - - Google Patents

Download PDF

Info

Publication number
JP2015534970A5
JP2015534970A5 JP2015537264A JP2015537264A JP2015534970A5 JP 2015534970 A5 JP2015534970 A5 JP 2015534970A5 JP 2015537264 A JP2015537264 A JP 2015537264A JP 2015537264 A JP2015537264 A JP 2015537264A JP 2015534970 A5 JP2015534970 A5 JP 2015534970A5
Authority
JP
Japan
Prior art keywords
multiple myeloma
cyclodextrin
sulfoalkyl ether
group
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015537264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/071779 external-priority patent/WO2014060548A1/de
Publication of JP2015534970A publication Critical patent/JP2015534970A/ja
Publication of JP2015534970A5 publication Critical patent/JP2015534970A5/ja
Ceased legal-status Critical Current

Links

JP2015537264A 2012-10-17 2013-10-17 多発性骨髄腫の治療のためのアントシアニジン複合体 Ceased JP2015534970A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12188789 2012-10-17
EP12188789.7 2012-10-17
PCT/EP2013/071779 WO2014060548A1 (de) 2012-10-17 2013-10-17 Anthocyanidin-komplex zur behandlung von multiplem myelom

Publications (2)

Publication Number Publication Date
JP2015534970A JP2015534970A (ja) 2015-12-07
JP2015534970A5 true JP2015534970A5 (enExample) 2016-11-10

Family

ID=47115385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015537264A Ceased JP2015534970A (ja) 2012-10-17 2013-10-17 多発性骨髄腫の治療のためのアントシアニジン複合体

Country Status (8)

Country Link
US (1) US20150258202A1 (enExample)
EP (1) EP2908829A1 (enExample)
JP (1) JP2015534970A (enExample)
KR (1) KR20150070303A (enExample)
CN (1) CN104780925A (enExample)
CA (1) CA2887057A1 (enExample)
HK (1) HK1212590A1 (enExample)
WO (1) WO2014060548A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2890022C (en) 2012-11-15 2020-07-14 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CA2893883A1 (en) 2012-12-11 2014-06-19 Sapiotec Gmbh Delphinidin for combating melanoma cells
KR102050639B1 (ko) 2017-11-08 2019-11-29 경희대학교 산학협력단 왕불류행 추출물을 포함하는 암의 예방 및 치료용 조성물
KR101982937B1 (ko) 2017-11-08 2019-05-27 경희대학교 산학협력단 천궁 추출물을 포함하는 암의 예방 및 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
ES2235642B2 (es) * 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2792733C (en) * 2010-03-13 2015-06-02 Eastpond Laboratories Limited Fat-binding compositions comprising .alpha.- or .beta.-cyclodextrin
RU2013133723A (ru) * 2010-12-31 2015-02-10 Истпонд Лабораториз Лимитед Композиции для клеточной гидратации, содержащие циклодекстрины
US20150051273A1 (en) * 2012-03-30 2015-02-19 Sapiotec Gmbh Use of delphinidin against staphylococcus aureus
KR101905937B1 (ko) * 2012-03-30 2018-10-08 자피오텍 게엠베하 안토시아니딘 복합체

Similar Documents

Publication Publication Date Title
Vo et al. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs
Singh Impact of product-related factors on immunogenicity of biotherapeutics
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
JP2015534970A5 (enExample)
MX2013015005A (es) Microparticulas de dicetopiperazina de alta capacidad.
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
JP2015212268A5 (enExample)
AR081575A1 (es) Formas de dosificacion oral de bendamustina y su uso terapeutico
PE20110583A1 (es) Comprimidos de capecitabina de disgregacion rapida
JP2015510916A5 (enExample)
JP2017503014A5 (enExample)
JP2015520241A5 (enExample)
RU2015143475A (ru) Продукт и способ лечения диареи
WO2013192610A3 (en) Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
MX375187B (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras.
JP2014058509A5 (enExample)
Koneri et al. Antiangiogenic and anticancer activity of saponins of Momordica cymbalaria.
JP2013541582A5 (enExample)
JP2017513866A5 (enExample)
CN102675338A (zh) 微粉化普拉格雷及其药用组合物
CN103239400B (zh) 一种伊曲康唑纳米混悬剂及其制备方法
CN102670532B (zh) 伊潘立酮药物组合物及其制备方法
JP2016502985A5 (enExample)
Gholamzadeh et al. The effect of cyclodextrin mixtures on aqueous solubility of beclomethasone dipropionate
JP2015505553A5 (enExample)